Table 2 Changes in organ damage before and after the introduction of MPZ
Pre-MPZ | Post-MPZ | ||||||||
|---|---|---|---|---|---|---|---|---|---|
-12 M | -11 M | -9 M | -6 M | 0 M | 1 M | 3 M | 6 M | 12 M | |
General symptoms | 0 | 0 | 1 (6.3%) | 1 (6.3%) | 1 (6.3%) | 1 (6.3%) | 0 | 1 (6.3%) | 0 |
Cutaneous manifestations | 1 (6.3%) | 1 (6.3%) | 1 (6.3%) | 1 (6.3%) | 2 (12.5%) | 2 (12.5%) | 0 | 1 (6.3%) | 0 |
ENT manifestations | 6 (37.5%) | 6 (37.5%) | 6 (37.5%) | 6 (37.5%) | 6 (37.5%) | 6 (37.5%) | 6 (37.5%) | 4 (25.0%) | 3 (18.8%) |
Chest manifestations | 6 (37.5%) | 6 (37.5%) | 8 (50.0%) | 8 (50.0%) | 11 (68.8%) | 5 (31.3%) | 2 (12.5%) | 2 (12.5%) | 2 (12.5%) |
Nervous system manifestations | 7 (45.8%) | 7 (45.8%) | 7 (45.8%) | 8 (50.0%) | 8 (50.0%) | 8 (50.0%) | 7 (43.8%) | 7 (43.8%) | 7 (43.8%) |